抗体

单克隆抗体载脂蛋白b(载脂蛋白B)

MBS2090608

0.01毫克

105美元

单克隆

小鼠

未共轭

[D7]

免疫印迹, 免疫组化, 免疫细胞化学, 免疫沉淀

抗体

单克隆抗体载脂蛋白b(载脂蛋白B)

[载脂蛋白b(载脂蛋白B)]

[载脂蛋白B;FLDB;载脂蛋白B-100;载脂蛋白B-48]

[载脂蛋白b-100;载脂蛋白b-100;载脂蛋白b-100;载脂蛋白b]

[载脂蛋白B]

[载脂蛋白B;载脂蛋白B;FLDB;LDLCQ4;载脂蛋白B 48;载脂蛋白B 100;载脂蛋白B-100;载脂蛋白B-48]

单克隆

IgG2a Kappa

[D7]

小鼠

蛋白质A+蛋白质G亲和色谱

Supplied as solution form in 0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.

1毫克/毫升

Storage: Avoid repeated freeze/thaw cycles. Store at 4ºC for frequent use. Aliquot and store at -20ºC for 24 months. Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

免疫印迹(免疫印迹), 免疫组化(免疫组化), 免疫细胞化学(免疫细胞化学), 免疫沉淀(免疫沉淀)

Western blotting: 0.5-5ug/mL. Immunohistochemistry: 5-20ug/mL. Immunocytochemistry: 5-20ug/mL. Optimal working dilutions must be determined by end user.

免疫印迹(免疫印迹)

免疫组化(免疫组化)

免疫印迹(免疫印迹)

Organism Species: Homo sapiens (Human). Source: Monoclonal antibody preparation. Traits: Liquid

Immunogen: Recombinant APOB expressed in E.coli

105990532

NP_000375.2

NM_000384.2

P04114

Binding And Uptake Of Ligands By Scavenger Receptors Pathway (771599); Cell Surface Interactions At The Vascular Wall Pathway (106062); Chylomicron-mediated Lipid Transport Pathway (106157); Disease Pathway (530764); Diseases Associated With Visual Transduction Pathway (771581); FOXA1 Transcription Factor Network Pathway (137979); Fat Digestion And Absorption Pathway (194385); Fat Digestion And Absorption Pathway (194324); Hemostasis Pathway (106028); LDL-mediated Lipid Transport Pathway (106159)

This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA- UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Jul 2008]

APOB: Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. Defects in APOB are a cause of familial hypobetalipoproteinemia type 1 (FHBL1). A disorder characterized by highly reduced plasma concentrations of low density lipoproteins, and dietary fat malabsorption. Clinical presentation may vary from no symptoms to severe gastrointestinal and neurological dysfunction similar to abetalipoproteinemia. Defects in APOB are a cause of familial ligand-defective apolipoprotein B-100 (FDB). FDB is a dominantly inherited disorder of lipoprotein metabolism leading to hypercholesterolemia and increased proneness to coronary artery disease (CAD). The plasma cholesterol levels are dramatically elevated due to impaired clearance of LDL particles by defective APOB/E receptors. Defects in APOB associated with defects in other genes (polygenic) can contribute to hypocholesterolemia. Protein type: Carrier; Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 2p24.1. Cellular Component: cell soma; chylomicron; chylomicron remnant; cytoplasm; cytosol; early endosome; endocytic vesicle lumen; endoplasmic reticulum exit site; endoplasmic reticulum lumen; endoplasmic reticulum membrane; endosome membrane; extracellular exosome; extracellular region; extracellular space; intermediate-density lipoprotein particle; intracellular membrane-bound organelle; low-density lipoprotein particle; lysosomal lumen; mature chylomicron; plasma membrane; smooth endoplasmic reticulum; very-low-density lipoprotein particle. Molecular Function: cholesterol transporter activity; heparin binding; low-density lipoprotein receptor binding; phospholipid binding; protein binding. Biological Process: artery morphogenesis; cellular protein metabolic process; cellular response to prostaglandin stimulus; cellular response to tumor necrosis factor; cholesterol efflux; cholesterol homeostasis; cholesterol metabolic process; cholesterol transport; chylomicron assembly; chylomicron remnant clearance; chylomicron remodeling; fertilization; in utero embryonic development; leukocyte migration; lipoprotein biosynthetic process; lipoprotein catabolic process; lipoprotein transport; low-density lipoprotein particle clearance; low-density lipoprotein particle remodeling; nervous system development; positive regulation of cholesterol storage; positive regulation of gene expression; positive regulation of lipid storage; positive regulation of macrophage derived foam cell differentiation; post-embryonic development; post-translational protein modification; receptor-mediated endocytosis; regulation of cholesterol biosynthetic process; response to carbohydrate stimulus; response to estradiol; response to lipopolysaccharide; response to selenium ion; response to virus; retinoid metabolic process; sperm motility; spermatogenesis; toll-like receptor signaling pathway; triacylglycerol mobilization; triglyceride catabolic process; very-low-density lipoprotein particle assembly. Disease: Hypercholesterolemia, Autosomal Dominant, Type B; Hypobetalipoproteinemia, Familial, 1

0.01毫克

105美元

0.02毫克

110

0.05毫克

145

0.1毫克

175

0.2毫克

230

1毫克

515